NCT06773767View on ClinicalTrials.gov

Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state.

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

August 7, 2024

Study Completion Date

August 7, 2024

Conditions
Bioavailability Heathy VolunteersBioavailability StudyBioequivalance
Interventions
DRUG

150 mg trazodone hydrochloride

To compare the bioavailability of 150 mg trazodone hydrochloride tablets (new polymer) vs. 150 mg trazodone hydrochloride Contramid® tablets at steady-state.

DRUG

300 mg trazodone hydrochloride

To compare the bioavailability of 300 mg trazodone hydrochloride tablets (new polymer) vs. 300 mg trazodone hydrochloride Contramid® tablets at steady-state

Trial Locations (1)

99084

SocraTec R&D GmbH Clinical Pharmacology, Erfurt

All Listed Sponsors
collaborator

SocraTec R&D GmbH

OTHER

lead

Aziende Chimiche Riunite Angelini Francesco S.p.A

INDUSTRY

NCT06773767 - Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state. | Biotech Hunter | Biotech Hunter